PFE Add to watchlist
$24.48 +0.00 (+0.00%)
Pre-Market: $24.25 0.23 (-0.94%)
Last updated: Jul 15, 2026 10:22
52-Week Range
$24.25
$23.11 $24.25 $28.75

Fundamentals Overview

Pfizer Inc. is near the low of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 18.6 P/B 1.53 P/S 2.18

Intrinsic value (DCF)

+61.2% upside vs price

Profitability

Net margin 11.8%

Risk (Beta)

0.31 — lower vol

Earnings & growth

EPS $1.31 Rev -17.7% Profit +263.1% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 60% confidence Risk: Lower Volatility — Beta 0.31. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +61.2% upside vs price · Analyst grade: B

Pressures (Sell):

3M vs S&P 500: -20.9% · 3M vs Healthcare sector: -18.3%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$138.21B
P/E (TTM)
18.55
EPS (TTM)
$1.31
Dividend Yield
7.09%
52-Week Range
$23.11 - $28.75
Volume vs Avg
N/A
Beta
0.31

About

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplifie...
Sector: Healthcare
Headquarters: US
Employees: 75,000
IPO Date: Jun 1972
Beta: 0.31 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B. Recent institutional grades: mixed. Current institutional positions: Buy: 6, Equal Weight: 5, Hold: 1, Neutral: 15, Outperform: 1, Sector Perform: 1, Underperform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $39.09; current price is $24.25. That’s a +61.2% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 18.55
DCF value (model) $39.09 (61.2% upside)
PEG (TTM) N/A
P/B (TTM) 1.53
P/S (TTM) 2.18
P/FCF (TTM) 14.57
Liquidity & enterprise
Current Ratio (TTM) 1.25
Quick Ratio (TTM) 0.94
Cash Ratio (TTM) 0.05
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 11.83%
Gross margin (TTM) 69.35%
Operating margin (TTM) 23.45%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for PFE.

Analyst Sentiment at a Glance

B Sentiment Mixed
Buy 6Equal Weight 5Hold 1Neutral 15Outperform 1Sector Perform 1Underperform 1
2 upgrades, 2 downgrades
Price Target Consensus
Current $24.25
Median $27.00
Consensus $26.89
Low consensus $25.00
High consensus $30.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Guggenheim maintain Buy Buy 2026-07-13
BMO Capital maintain Outperform Outperform 2026-07-13
B of A Securities maintain Neutral Neutral 2026-07-10
JP Morgan maintain Neutral Neutral 2026-07-08
HSBC downgrade Buy Hold 2026-07-06
Cantor Fitzgerald maintain Neutral Neutral 2026-07-06
RBC Capital upgrade Underperform Sector Perform 2026-06-10
Citigroup maintain Neutral Neutral 2026-04-29
RBC Capital maintain Underperform Underperform 2026-04-20
UBS maintain Neutral Neutral 2026-04-13
Morgan Stanley maintain Equal Weight Equal Weight 2026-04-10
B of A Securities maintain Neutral Neutral 2026-04-09
Guggenheim maintain Buy Buy 2026-03-24
HSBC maintain Buy Buy 2026-03-17
Argus Research upgrade Hold Buy 2026-03-02
Freedom Broker maintain Buy Buy 2026-02-09
Cantor Fitzgerald maintain Neutral Neutral 2026-02-04
Cantor Fitzgerald maintain Neutral Neutral 2026-01-27
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-17
B of A Securities maintain Neutral Neutral 2025-12-15
Morgan Stanley maintain Equal Weight Equal Weight 2025-12-12
Guggenheim maintain Buy Buy 2025-11-24
Morgan Stanley maintain Equal Weight Equal Weight 2025-10-10
B of A Securities maintain Neutral Neutral 2025-10-03
Citigroup maintain Neutral Neutral 2025-08-06
B of A Securities maintain Neutral Neutral 2025-08-06
Morgan Stanley maintain Equal Weight Equal Weight 2025-08-06
UBS maintain Neutral Neutral 2025-04-30
Goldman Sachs downgrade Buy Neutral 2025-04-08
UBS maintain Neutral Neutral 2025-04-08